Search

Novo Nordisk A-S (Class B)

Cerrado

921.9 0.79

Resumen

Variación precio

24h

Actual

Mínimo

918.8

Máximo

923

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+9.53 upside

Novo Nordisk A-S (Class B) Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

7 ago 2024, 10:13 UTC

Ganancias

Novo Nordisk's Wegovy Sales Disappoint -- 2nd Update

7 ago 2024, 06:58 UTC

Ganancias

Wegovy Maker Novo Nordisk Lifts Sales Guidance as Weight-Loss Drug Demand Continues to Surge -- Update

12 sept 2024, 13:00 UTC

Principales Noticias

Senators Target Influencers, Telehealth Firms for Misleading Weight-Loss and Other Drug Promotion -- WSJ

12 sept 2024, 11:45 UTC

Charlas de Mercado
Ganancias

Novo Nordisk's Obesity Pill Data Confirm Investor Optimism -- Market Talk

12 sept 2024, 10:30 UTC

Charlas de Mercado
Ganancias

Novo Nordisk's Amycretin Obesity Pill Slightly Disappoints on Safety -- Market Talk

11 sept 2024, 12:08 UTC

Principales Noticias

Novo Nordisk Stock Rises After Study Finds Obesity Drug Safe For Kids -- Barrons.com

9 sept 2024, 07:56 UTC

Charlas de Mercado

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

3 sept 2024, 11:09 UTC

Principales Noticias

Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly. -- Barrons.com

27 ago 2024, 05:30 UTC

Principales Noticias

Weight-Loss Drugs Get More Good News. For Investors, It's Still Too Soon to Celebrate. -- Barrons.com

14 ago 2024, 12:01 UTC

Charlas de Mercado
Ganancias

Novo Nordisk's Pricing and Pipeline to Remain Hot Topics -- Market Talk

9 ago 2024, 11:30 UTC

Principales Noticias

Eli Lilly Is Gaining on Novo Nordisk in the Obesity Race -- Heard on the Street -- WSJ

9 ago 2024, 07:30 UTC

Charlas de Mercado

Novo Nordisk Share Pullback Represents Great Opportunity -- Market Talk

8 ago 2024, 15:44 UTC

Principales Noticias
Ganancias

Eli Lilly Shows We Haven't Hit Peak Obesity Yet -- WSJ

8 ago 2024, 11:36 UTC

Charlas de Mercado
Ganancias

Novo Nordisk's Share-Price Weakness Provides an Opportunity -- Market Talk

8 ago 2024, 07:16 UTC

Charlas de Mercado
Ganancias

Novo Nordisk's Share-Price Drop Provides Buying Opportunity -- Market Talk

7 ago 2024, 20:30 UTC

Principales Noticias

Eli Lilly Reports Earnings Thursday Amid a Stock Slump. Here's What to Expect. -- Barrons.com

7 ago 2024, 16:39 UTC

Ganancias

Novo Nordisk's Wegovy Sales Disappoint -- Update

7 ago 2024, 15:30 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Novo Nordisk's Wegovy Sales Disappoint -- WSJ

7 ago 2024, 14:22 UTC

Principales Noticias
Ganancias

It Isn't Time to Worry About Wegovy Yet -- Heard on the Street -- WSJ

7 ago 2024, 12:28 UTC

Charlas de Mercado
Ganancias

Novo Nordisk's Core Products Disappoint -- Market Talk

7 ago 2024, 12:04 UTC

Ganancias

Novo Nordisk Execs Were Speaking on a Call After 2Q Earnings

7 ago 2024, 11:34 UTC

Ganancias

Novo Nordisk US Head: As Wegovy Volumes Go Up, Prices Will Come Down

7 ago 2024, 11:34 UTC

Ganancias

Novo Nordisk CEO: When You Move Into New Sales Channels it Comes With a Discount

7 ago 2024, 11:34 UTC

Ganancias

Novo Nordisk CEO: Wegovy Now Covered in 20 States Through Medicaid

7 ago 2024, 11:05 UTC

Charlas de Mercado
Ganancias

Novo Nordisk Delivers Messy Quarter as Wegovy Misses The Mark -- Market Talk

7 ago 2024, 10:55 UTC

Ganancias

Stock Market Madness Highlights This Problem for -2-

7 ago 2024, 10:55 UTC

Ganancias

Stock Market Madness Highlights This Problem for Novo Nordisk and Super Micro. And 5 Other Things to Know Today. -- Barrons.com

7 ago 2024, 09:07 UTC

Ganancias
Acciones populares

Stocks to Watch Wednesday: Super Micro, Rivian, Airbnb -- WSJ

7 ago 2024, 08:55 UTC

Principales Noticias

These Stocks Are Moving the Most Today: Super Micro, Lumen, Airbnb, Rivian, Fortinet, Upstart, Disney, and More -- Barrons.com

7 ago 2024, 07:32 UTC

Charlas de Mercado
Ganancias

Novo Nordisk Wegovy Sales Disappoint -- Market Talk

Novo Nordisk A-S (Class B) Esperado

Precio Objetivo

By TipRanks

9.53% repunte

Estimación a 12 meses

Media 1,162.73 DKK  9.53%

Máximo 1,550 DKK

Mínimo 720 DKK

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novo Nordisk A-S (Class B) Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

7

Comprar

2

Mantener

2

Vender